Analyst Price Targets — NXTC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 15, 2025 10:46 am | Edward Tenthoff | Piper Sandler | $15.00 | $4.76 | TheFly | NextCure price target lowered to $15 from $36 at Piper Sandler |
| June 3, 2024 8:19 am | Edward Tenthoff | Piper Sandler | $3.00 | $1.52 | StreetInsider | Piper Sandler Reiterates Overweight Rating on NextCure Inc. (NXTC) |
| November 3, 2022 9:20 pm | Edward Tenthoff | Piper Sandler | $6.00 | $2.51 | TheFly | NextCure price target lowered to $6 from $13 at Piper Sandler |
Latest News for NXTC
BELTSVILLE, Md., Jan. 23, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today provided updates for its two antibody drug conjugate (ADC) programs and reported a preliminary year-end 2025 cash position.
NextCure, Inc. (NASDAQ: NXTC - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totaling 26,706 shares, a growth of 29.6% from the November 30th total of 20,613 shares. Based on an average trading volume of 45,355 shares, the days-to-cover ratio is
Monte Rosa Therapeutics (NASDAQ: GLUE - Get Free Report) and NextCure (NASDAQ: NXTC - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk. Volatility and Risk Monte Rosa Therapeutics has
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NXTC.
U.S. House Trading
No House trades found for NXTC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.